The high development costs associated with digital dose inhalers is a major factor restraining the market growth. Developing an inhaler that can precisely track dose usage, connect to a mobile app, and adhere to strict medical regulations is an expensive endeavor that requires significant investments in R&D. Digital dose inhalers uses sensors, connectivity modules, and complex software, and this drive up manufacturing costs as compared to conventional inhalers. Digital inhalers must undergo lengthy and rigorous clinical trials to prove their safety, efficacy, and consistency in drug delivery over traditional devices. This clinical trial process alone spans several years and costs millions of dollars. However, the lengthy patenting process also translates to delays in being able to generate revenues. This discourages many smaller companies from investing in this emerging field despite the potential benefits of digital monitoring and connectivity for patients. Moreover, due to the high prices necessitated by the development expenditures, digital inhalers may not be affordable or reimbursed for all patients. This could limit their widespread adoption, especially in developing countries.
Market Opportunities – The Digitization of Inhalers Presents a Major Opportunity for More Personalized Care
The digitization of inhalers presents a major opportunity for more personalized care. Detailed usage data provides insights into how treatment regimens are working in real-world settings. This data can help physicians better understand triggers for asthmatic episodes or COPD flare ups. It also enables remote monitoring that improves access and convenience for patients managing chronic conditions.
Digital Dose Inhaler Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients